{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:07:03Z","timestamp":1754161623706,"version":"3.41.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1023\/b:ddas.0000034551.39324.c3","type":"journal-article","created":{"date-parts":[[2004,7,13]],"date-time":"2004-07-13T22:48:50Z","timestamp":1089758930000},"page":"931-936","source":"Crossref","is-referenced-by-count":31,"title":["On-Demand Therapy with Rabeprazole in Nonerosive and Erosive Gastroesophageal Reflux Disease in Clinical Practice: Effectiveness, Health-Related Quality of Life, and Patient Satisfaction"],"prefix":"10.1007","volume":"49","author":[{"given":"Julian","family":"Ponce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Arg\u00fcello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Bastida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Garrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"Suppl","key":"492750_CR1","first-page":"3","volume":"231","author":"RC. Heading","year":"1999","unstructured":"Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: A systematic review. Scand J Gastroenterol 231(Suppl): 3\u20138, 1999","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl4A","key":"492750_CR2","doi-asserted-by":"crossref","first-page":"99S","DOI":"10.1016\/S0002-9343(99)00347-2","volume":"108","author":"JF Johanson","year":"2000","unstructured":"Johanson JF: Epidemiology of esophageal and supraesophageal reflux injuries. Am J Med 108(Suppl 4A): 99S\u2013103S, 2000","journal-title":"Am J Med"},{"key":"492750_CR3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0002-9343(97)00354-9","volume":"104","author":"DA Revicki","year":"1998","unstructured":"Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 104: 252\u2013258, 1998","journal-title":"Am J Med"},{"key":"492750_CR4","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/j.1572-0241.1999.01206.x","volume":"94","author":"T Havelund","year":"1999","unstructured":"Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, Lundell L, Pedersen SA, Carlsson R, Junghard O, Stubberod A, Anker-Hansen O: Quality of life in patients with heartburn but without esophagitis: Effects of treatment with omeprazole. Am J Gastroenterol 94: 1782\u20131789, 1999","journal-title":"Am J Gastroenterol"},{"key":"492750_CR5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1053\/gast.2000.16484","volume":"119","author":"IM Gralnek","year":"2000","unstructured":"Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119: 654\u2013660, 2000","journal-title":"Gastroenterology"},{"key":"492750_CR6","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/j.1572-0241.2000.02235.x","volume":"95","author":"MA Eloubeidi","year":"2000","unstructured":"Eloubeidi MA, Provenzale D: Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol 95: 1881\u20131887, 2000","journal-title":"Am J Gastroenterol"},{"key":"492750_CR7","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","volume":"112","author":"N Chiba","year":"1997","unstructured":"Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 112: 1798\u20131810, 1997","journal-title":"Gastroenterology"},{"key":"492750_CR8","volume-title":"The Cochrane Library","author":"B van Pinxteren","year":"2000","unstructured":"van Pinxteren B, Numans ME, Bonis PA, Lau J: Short-term treatment with proton pump inihibitors, H2-receptor antagonists and prokinetics for gastroesophageal reflux disease-like symptoms and endoscopy negative reflux disease (Cochrane Review). The Cochrane Library, Issue 2, Oxford, Update Software, 2000"},{"key":"492750_CR9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/gut.33.8.1016","volume":"33","author":"NE Schindlbeck","year":"1992","unstructured":"Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA: Three year follow-up of patients with gastroesophageal reflux disease. Gut 33: 1016\u20131019, 1992","journal-title":"Gut"},{"key":"492750_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00042737-199802000-00004","volume":"10","author":"R Carlsson","year":"1998","unstructured":"Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalvag A, Junghard O, Wiklund I. Gastroesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORDStudy Group. Eur J Gastroenterol Hepatol 10: 119\u2013124, 1998","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"Suppl2","key":"492750_CR11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/gut.44.2008.S1","volume":"44","author":"J Dent","year":"1999","unstructured":"Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NJ: An evidence-based appraisal of reflux disease management\u2014The Genval Workshop report. Gut 44(Suppl 2): S1\u2013S16, 1999","journal-title":"Gut"},{"key":"492750_CR12","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/bmj.318.7182.502","volume":"318","author":"KD Bardhan","year":"1999","unstructured":"Bardhan KD, Muller-Lissner S, Bigard MA, Porro GB, Ponce J, Hosie J, Scott M, Weir DG, Gillon KR, Peacock RA, Fulton C: Symptomatic gastroesophageal reflux disease: Double blind controlled study of intermittent treatment with omprazole or ranitidine. Br Med J 318: 502\u2013507, 1999","journal-title":"Br Med J"},{"key":"492750_CR13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1365-2036.1999.00564.x","volume":"13","author":"T Lind","year":"1999","unstructured":"Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberod A, Eriksson G, Carlsson R, Junghard O: On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis\u2014A placebo-controlled randomized trial. Aliment Pharmacol Ther 13: 907\u2013914, 1999","journal-title":"Aliment Pharmacol Ther"},{"key":"492750_CR14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2036.2001.00943.x","volume":"15","author":"NJ Talley","year":"2001","unstructured":"Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, Schulz T,Omland TM, Delle M, Junghard O: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastroesophageal reflux disease: a controlled trial of \u201con-demand\u201d therapy for 6 months. Aliment Pharmacol Ther 15: 347\u2013354, 2001","journal-title":"Aliment Pharmacol Ther"},{"key":"492750_CR15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/00042737-200208000-00008","volume":"14","author":"NJ Talley","year":"2002","unstructured":"Talley NJ, Venables TL, Green JR, Armstrong D, O'Kane KP, Giaffer M, Bardhan KD, Carlsson RG, Chen S, Hasselgren GS: Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastroesophageal reflux disease: A placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 14: 857\u2013863, 2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"492750_CR16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/gast.1996.v111.pm8698230","volume":"111","author":"D Armstrong","year":"1996","unstructured":"Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, Lundell L, Margulies M, Richter JE, Spechler SJ, Tytgat GN, Wallin L: The endocopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 111: 85\u201392, 1996","journal-title":"Gastroenterology"},{"key":"492750_CR17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473\u2013483, 1992","journal-title":"Med Care"},{"key":"492750_CR18","first-page":"771","volume":"104","author":"J Alonso","year":"1995","unstructured":"Alonso J, Prieto L, Anto JM: The spanish version of the SF-36 health survey (the SF-36 health questionnaire): An instrument for measuring clinical results. Med Clin (Barc) 104: 771\u2013776, 1995","journal-title":"Med Clin (Barc)"},{"key":"492750_CR19","first-page":"410","volume":"111","author":"J Alonso","year":"1998","unstructured":"Alonso J, Regidor E, Barrio G, Prieto L, Rodriguez C, De la Fuente L: Population reference values of the Spanish version of the Health Questionnaire SF-36. Med Clin (Barc) 111: 410\u2013416, 1998","journal-title":"Med Clin (Barc)"},{"key":"492750_CR20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/02770900009055440","volume":"37","author":"L Compte","year":"2000","unstructured":"Compte L, Garrigues V, Perpi\u00f1\u00e1 M, Ponce J: Prevalence of gastroesophageal reflux in asthma. J Asthma 37: 175\u2013182, 2000","journal-title":"J Asthma"},{"key":"492750_CR21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1572-0241.2000.01759.x","volume":"95","author":"LB Gerson","year":"2000","unstructured":"Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G: A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. AmJ Gastroenterol 95: 395\u2013407, 2000","journal-title":"AmJ Gastroenterol"},{"key":"492750_CR22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2036.1999.00438.x","volume":"13","author":"CP Dekkers","year":"1999","unstructured":"Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastroesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 13: 49\u201357, 1999","journal-title":"Aliment Pharmacol Ther"},{"key":"492750_CR23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1572-0241.2002.05769.x","volume":"97","author":"P Miner","year":"2002","unstructured":"Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S: Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial. Am J Gastroenterol 97: 1332\u20131339, 2002","journal-title":"Am J Gastroenterol"},{"key":"492750_CR24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2036.2002.01181.x","volume":"16","author":"M Robinson","year":"2002","unstructured":"Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L: Onset of symptom relief with rabeprazole: A community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 16: 445\u2013454, 2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl1","key":"492750_CR25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2036.17.s1.10.x","volume":"17","author":"J Dent","year":"2003","unstructured":"Dent J, Talley NJ: Overview: Initial and long-term management of gastroesophageal reflux disease. Aliment Pharmacol Ther 17(Suppl 1): 53\u201357, 2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl1","key":"492750_CR26","first-page":"S19","volume":"13","author":"P Bytzer","year":"2001","unstructured":"Bytzer P: On-demand therapy for gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 13(Suppl 1): S19\u2013S22, 2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"492750_CR27","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1365-2036.1998.00418.x","volume":"12","author":"MP Williams","year":"1998","unstructured":"Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabepra-zole versus omeprazole on 24-hour intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12: 1079\u20131089, 1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl213","key":"492750_CR28","first-page":"25","volume":"30","author":"RC Heading","year":"1995","unstructured":"Heading RC: Long-term management of gastro oesophageal reflux disease. Scand J Gastroenterol 30(Suppl 213): 25\u201330, 1995","journal-title":"Scand J Gastroenterol"},{"key":"492750_CR29","first-page":"463","volume":"49","author":"AP Hungin","year":"1999","unstructured":"Hungin AP, Rubin G, O'Flanagan H: Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 49: 463\u2013464, 1999","journal-title":"Br J Gen Pract"},{"key":"492750_CR30","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1023\/A:1020532714664","volume":"47","author":"JF Johanson","year":"2002","unstructured":"Johanson JF, Siddique R, Damiano AM, Jokubaitis L, Murthy A, Bhattacharjya A: Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. Dig Dis Sci 47: 2574\u20132578, 2002","journal-title":"Dig Dis Sci"},{"key":"492750_CR31","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00019053-199916050-00006","volume":"16","author":"NO Stalhammar","year":"1999","unstructured":"Stalhammar NO, Carlsson J, Peacock R, Muller-Lissner S, Bigard MA, Porro GB, Ponce J, Hosie J, Scott M, Weir DG, Fulton C, Gillon K, Bardhan KD: Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastroesophageal reflux disease. Pharmacoeconomics 16: 483\u2013497, 1999","journal-title":"Pharmacoeconomics"},{"key":"492750_CR32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00019053-200220040-00005","volume":"20","author":"P Wahlqvist","year":"2002","unstructured":"Wahlqvist P, Junghard O, Higgins A, Green J: Cost-effectiveness of proton pump inhibitors in gastroesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 20: 267\u2013277, 2002","journal-title":"Pharmacoeconomics"},{"key":"492750_CR33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2165\/00019053-200220090-00001","volume":"20","author":"JM Inadomi","year":"2002","unstructured":"Inadomi JM: On-demand and intermittent therapy for gastroesophageal reflux disease: Economic considerations. Pharmacoeconomics 20: 565\u2013576, 2002","journal-title":"Pharmacoeconomics"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:DDAS.0000034551.39324.c3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/B:DDAS.0000034551.39324.c3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:DDAS.0000034551.39324.c3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T03:52:07Z","timestamp":1753761127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/B:DDAS.0000034551.39324.c3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["492750"],"URL":"https:\/\/doi.org\/10.1023\/b:ddas.0000034551.39324.c3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}